Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Neurotech Pharmaceuticals, Inc.

Neurotech Provides Corporate Update on Commercial Progress

March 12, 2026

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025

September 29, 2025

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors

September 02, 2025

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

First FDA-Approved Treatment for MacTel Performed

August 11, 2025

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Appoints Beth Marsh as Chief Commercial Officer

April 21, 2025

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)

March 06, 2025

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)

November 08, 2024

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel)

June 20, 2024

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Alex Gorsky Joins Neurotech’s Board as Lead Director

September 13, 2023

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer

January 10, 2023

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2

November 02, 2022

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Neurotech Pharmaceuticals Appoints Thomas Aaberg Jr., M.D. as Chief Medical Officer

November 01, 2021

From Neurotech Pharmaceuticals, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.